LLY

737.79

+2.36%↑

JNJ

154.98

+1.05%↑

ABBV

185.51

+0.1%↑

NVO

71.33

+2.71%↑

UNH

300.93

+0.94%↑

LLY

737.79

+2.36%↑

JNJ

154.98

+1.05%↑

ABBV

185.51

+0.1%↑

NVO

71.33

+2.71%↑

UNH

300.93

+0.94%↑

LLY

737.79

+2.36%↑

JNJ

154.98

+1.05%↑

ABBV

185.51

+0.1%↑

NVO

71.33

+2.71%↑

UNH

300.93

+0.94%↑

LLY

737.79

+2.36%↑

JNJ

154.98

+1.05%↑

ABBV

185.51

+0.1%↑

NVO

71.33

+2.71%↑

UNH

300.93

+0.94%↑

LLY

737.79

+2.36%↑

JNJ

154.98

+1.05%↑

ABBV

185.51

+0.1%↑

NVO

71.33

+2.71%↑

UNH

300.93

+0.94%↑

Search

Anavex Life Sciences Corp

Geschlossen

BrancheGesundheitswesen

7.51 -0.79

Übersicht

Veränderung der Aktienkurses

24h

Aktuell

Min

7.48

Max

7.55

Schlüsselkennzahlen

By Trading Economics

Einkommen

915K

-11M

EPS

-0.132

Angestellte

42

EBITDA

-779K

-13M

Empfehlungen

By TipRanks

Empfehlungen

Buy

12-Monats-Prognose

+278.49% upside

Dividenden

By Dow Jones

Nächstes Ergebnis

5. Aug. 2025

Marktstatistiken

By TradingEconomics

Marktkapitalisierung

-84M

643M

Vorheriger Eröffnungskurs

8.3

Vorheriger Schlusskurs

7.51

Nachrichtenstimmung

By Acuity

50%

50%

151 / 381 Ranking in Healthcare

Technischer Score

By Trading Central

Vertrauen

Very Strong Bearish Evidence

Anavex Life Sciences Corp Chart

Vergangene Performances sind kein verlässlicher Indikator für zukünftige Ergebnisse.

Ähnliche Nachrichten

31. Mai 2025, 10:30 UTC

Top News

Pension Funds Won't Save the Bond Market -- Heard on the Street -- WSJ

31. Mai 2025, 06:30 UTC

Ergebnisse

5 Things We've Learned From Retail Earnings -- Barrons.com

31. Mai 2025, 04:15 UTC

Market Talk

Global Commodities Roundup: Market Talk

30. Mai 2025, 23:51 UTC

Akquisitionen, Fusionen, Übernahmen

Trump Raises Steel Tariffs, Saying U.S. Steel Will Remain U.S.-Controlled -- Update

30. Mai 2025, 21:30 UTC

Top News

Stocks Shrug Off Trade War to Post Best Month Since 2023 -- WSJ

30. Mai 2025, 21:15 UTC

Top News

The Score: E.l.f. Beauty, Tesla, Nvidia, and More Stocks That Defined the Week -- WSJ

30. Mai 2025, 20:50 UTC

Market Talk
Akquisitionen, Fusionen, Übernahmen

Health Care Roundup: Market Talk

30. Mai 2025, 20:44 UTC

Akquisitionen, Fusionen, Übernahmen

Bill Ackman Is Killing It. A New ETF Will Track His Investments. -- Barrons.com

30. Mai 2025, 20:24 UTC

Top News

Major U.S. Stock Indexes Finish About Flat; U.S.-China Trade Friction Renews -- WSJ

30. Mai 2025, 20:15 UTC

Market Talk

Global Commodities Roundup: Market Talk

30. Mai 2025, 19:44 UTC

Market Talk

Gold Breaks 4-Month Winning Streak -- Market Talk

30. Mai 2025, 19:38 UTC

Market Talk

Companies Delay or Cancel $14B In Clean-Energy Investments -- Market Talk

30. Mai 2025, 19:29 UTC

Ergebnisse
Akquisitionen, Fusionen, Übernahmen

NRG Energy and UnitedHealth Are the S&P 500's Best and Worst for May. Here's Why. -- Barrons.com

30. Mai 2025, 19:14 UTC

Market Talk

Oil Settles Lower Ahead of OPEC+ Output Decision -- Market Talk

30. Mai 2025, 19:05 UTC

Market Talk

U.S. Natural Gas Futures Fall Awaiting Hotter Weather -- Market Talk

30. Mai 2025, 18:51 UTC

Market Talk

Canada's Retaliatory Tariffs Help Fuel Sizable Rise in Tax Revenue -- Market Talk

30. Mai 2025, 18:37 UTC

Market Talk
Ergebnisse

Costco Well Positioned for Sustainable Growth, UBS Says -- Market Talk

30. Mai 2025, 18:04 UTC

Top News

S&P 500 Falls After More Trump-China Friction -- WSJ

30. Mai 2025, 17:47 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

30. Mai 2025, 17:47 UTC

Market Talk

Time for BoC Gov. Macklem to Cut Rates, Desjardins Says -- Market Talk

30. Mai 2025, 17:40 UTC

Akquisitionen, Fusionen, Übernahmen

Trump Is Praising His U.S. Steel Deal. No One Is Sure What It Means -- WSJ

30. Mai 2025, 17:38 UTC

Market Talk

U.S: Oil Rig Count Falls for Fifth Straight Week -- Market Talk

30. Mai 2025, 17:31 UTC

Market Talk

Costco Well Positioned to Gain Share Amid Tariffs, Baird Says -- Market Talk

30. Mai 2025, 17:14 UTC

Top News

American Consumers Are Still Gloomy on the Economy -- 3rd Update

30. Mai 2025, 16:31 UTC

Ergebnisse

Ulta Beauty Stock Is Rising. Earnings Strength Was More Than Cosmetic. -- Barrons.com

30. Mai 2025, 16:20 UTC

Market Talk

Tech, Media & Telecom Roundup: Market Talk

30. Mai 2025, 16:20 UTC

Market Talk
Akquisitionen, Fusionen, Übernahmen

Health Care Roundup: Market Talk

30. Mai 2025, 16:16 UTC

Top News

S&P 500 Falls After Trump Hits Out at China -- WSJ

30. Mai 2025, 16:15 UTC

Market Talk

Global Commodities Roundup: Market Talk

30. Mai 2025, 16:14 UTC

Top News

HSBC Retreats From Banking Smaller U.S. Businesses -- WSJ

Peer-Vergleich

Kursveränderung

Anavex Life Sciences Corp Prognose

Kursziel

By TipRanks

278.49% Vorteil

12-Monats-Prognose

Durchschnitt 28.5 USD  278.49%

Hoch 42 USD

Tief 15 USD

Basierend auf 2 Wall-Street-Analysten, die in den letzten 3 Monaten 12-Monats-Kursziele für Anavex Life Sciences Corp – Dist angeboten haben.

Rating-Konsens

By TipRanks

Buy

2 ratings

2

Buy

0

Halten

0

Sell

Technischer Score

By Trading Central

8.275 / 9.312Unterstützung & Widerstand

Kurzfristig

Very Strong Bearish Evidence

Mittelfristig

Weak Bullish Evidence

Langfristig

Neutral Evidence

Stimmung

By Acuity

151 / 381 Ranking in Gesundheitswesen

Nachrichtenstimmung

Neutral

Volatilität

Unterdurchschnittlich

Nachrichtenvolumen (RCV)

Unterdurchschnittlich

Finanzen

Vertriebs- und Verwaltungskosten

Betriebsaufwand

Gewinn vor Steuern

Verkäufe

Zinsaufwand für Schulden

EBITDA

Betriebsergebnis

$

Über Anavex Life Sciences Corp

Anavex Life Sciences Corp., a clinical stage biopharmaceutical company, engages in the development of therapeutics for the treatment of central nervous system diseases. Its lead product candidate is ANAVEX 2-73 for the treatment of Alzheimer's disease and Parkinson's disease, as well as other central nervous system diseases, including rare diseases, such as Rett syndrome, a rare severe neurological monogenic disorder; and infantile spasms, Fragile X syndrome, and Angelman syndrome. The company's drug candidate also comprises ANAVEX 3-71, which is in clinical trial for the treatment of schizophrenia, frontotemporal dementia, and Alzheimer's disease. Its preclinical drug candidates include ANAVEX 1-41 for the treatment of depression, stroke, and neurogenerative disease; ANAVEX 1066 for the potential treatment of neuropathic and visceral pain; and ANAVEX 1037 to treat prostate and pancreatic cancer. The company was incorporated in 2004 and is headquartered in New York, New York.